IMVT — Immunovant Inc. stock price and chart

Share this page

IMVT

$26.73-2.84%

as of close, Oct 16, 2026

☾ AH $26.73 -2.84%

Immunovant Inc.Stock · HealthcareRussell 2000 0.1%Nasdaq Composite 0.02%Russell 3000 0.005%US Stock Market 0.004%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

Available history since Jun 26, 2019

VolumeEEEE

20192021202320242026

5.010.015.020.025.030.035.040.045.050.0020.0M40.0M$26.73

2026-10-16

Price$26.73

MA20$37.25

MA50$31.88

Vol1.5M

What would $1,000 invested in IMVT be worth today? →

IMVT returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $26.73
YTD price return: +5.15%
YTD total return: +5.15%
Next earnings: Nov 9, 2026
Market cap: 5.5B2019-06 140.9M2026-10 5.5B+3822.9% over the window
Enterprise value: 4.7B
Shares outstanding: 206.6M2019-03 14.4M2026-06 206.6M+1336.9% over the window
52W low: $17.03
52W high: $45.42
From 52W high: -41.15%
From 52W low: +57.00%
52W range: 34%

Volume

Rel volume: 0.94×
30D volume: 1.6M
30D $ vol: 52.4M

Fundamentals

EPS (ttm): -$2.822020-06 -$1.812026-06 -$2.82+55.9% over the window
FCF (ttm): -407.3M2019-03 -28.6M2026-03 -407.3M+1324.2% over the window
FCF/share: -$1.972019-03 -$1.992026-03 -$1.98-0.3% over the window
Book value/share: $3.562019-03 $0.512026-06 $3.56+597.4% over the window
ROE: -73.19%2019-03 -389.7%2026-06 -73.2%-81.2% over the window
ROA: -63.13%2019-03 -206.8%2026-06 -63.1%-69.5% over the window
Current ratio: 7.272019-03 41.872026-06 7.27-82.6% over the window

Growth (CAGR, ttm) · 10Y

Shares: +18.51%2025-06-30 → 2026-06-30174.3M → 206.6M (+18.5% total)+16.48%2023-06-30 → 2026-06-30130.7M → 206.6M (+58.1% total)+12.43%2021-06-30 → 2026-06-30115M → 206.6M (+79.6% total)n/a

Per-share growth (CAGR, ttm) · 10Y

Book value/share: +1.99%2025-06-30 → 2026-06-30$3.49 → $3.56 (+2.0% total)+15.76%2023-06-30 → 2026-06-30$2.29 → $3.56 (+55.1% total)+2.29%2021-06-30 → 2026-06-30$3.18 → $3.56 (+12.0% total)n/a
Price: +53.58%2025-10-16 → 2026-10-16$17.41 → $26.73 (+53.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-10.87%2023-10-16 → 2026-10-16$37.75 → $26.73 (-29.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+25.10%2021-10-15 → 2026-10-16$8.72 → $26.73 (+206.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/a
Total return: +53.58%2025-10-16 → 2026-10-16$17.41 → $26.73 (+53.5% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-10.87%2023-10-16 → 2026-10-16$37.75 → $26.73 (-29.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+25.10%2021-10-15 → 2026-10-16$8.72 → $26.73 (+206.5% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: -9.5×2019-06 -4.932026-10 -10.27+108.4% over the window
Fwd P/E: -11.1×
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 7.5×2019-06 19.202026-10 7.51-60.9% over the window
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: -7.38%2019-03 -20.3%2026-03 -8.0%-60.7% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 206.6M ÷ 174.3M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -18.51%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-18.51%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($2.8B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -18.51%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($-544.2M) ÷ today's market cap ($5.5B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: -9.86%2020-03 0.0%2026-06 -6.8%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $-544.2M + TTM dividends $0) ÷ today's market cap ($5.5B). Same caveat as the cash buyback yield.: -9.86%2020-03 0.0%2026-06 -6.8%

Vs own 10Y history

P/B: 57th

Bar = where today’s multiple sits in IMVT’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-2.84%

-12.27%

-26.53%

-31.39%

YTD

+5.15%

+53.53%

+206.54%

Financial statements

Open full IMVT financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

IMVT — Immunovant Inc. price, chart and key statistics